Evaluation of LDL goal achievement in statin consumption, south east of Iran

Abstract

Lipid goal achievement and statin consumption were estimated at extreme/very-high/high/moderate and low cardiovascular risk categories. In the cross-sectional study, 585 patients treated with statin therapy referring to the heart clinic of Birjand were recruited. Patients were classified and examined LDL-C values and the proportion reaching targets according to the American Association of Clinical Endocrinologists guideline. Three patterns of statin use (high/moderate/low-intensity statin therapy) in all patients were examined and attainments of LDL-C goal in cardiovascular risk groups have been demonstrated. Over half the populations (57.6%) were in the very-high CVD risk group. The results showed that the proportion of patients meeting total LDL-C goal values according to the guidelines was 43.4%. The frequency of patient had achievement LDL goal lower in high-intensity pattern (N = 13, 2.3%), compared with moderate (N = 496, 86.1%) and low-intensity patterns (N = 67, 11.6%). In general, LDL-C goal achievement was greatest with moderate-intensity statin use. LDL-C reduction after statin consumption was estimated about one-third of the studied population. It seems likely that the achievement of a therapeutic target for serum lipids such as LDL-C improved is far more cost-effective and would be able to reach the target LDL as well changing the type and intensity of statins.

Tracking of serum lipids in healthy children on a year-to-year basis

“…Not all serum lipids are equally suited as only TC, LDL-C and apolipoprotein B showed considerable stability. This is important as especially LDL-C is used for defining treatment goals in clinical settings [ 61 ]. The fact that adverse lipid profiles tend to be stable throughout childhood and adolescence suggests that children should be tested for dyslipidemia in early childhood to identify those with already elevated serum lipids.…”

Association of dietary and blood inflammatory indicators with depression, anxiety, and stress in adults with vitamin D deficiency

“…55,56 Depression is often accompanied by elevated levels of CRP, 57,58 and inflammation has been linked to depression through mechanisms such as insulin resistance and interactions with monoamine metabolism. [59][60][61] Higher scores on the AHEI-2010 are associated with a lower risk of CRP 62 and insulin resistance 63 due, in part, to a reduced risk of obesity. 64 The intake of foods with antiinflammatory properties, such as those included in the AHEI, may also reduce CRP levels through the antioxidant effects of n-3 fatty acids, dietary fiber, phytochemicals, carotenoids, and vitamin C. [65][66][67][68] These properties may also influence monoamine concentrations, which have been linked to high levels of depressive symptoms and inflammatory biomarkers.…”

“…One potential factor is the anti‐inflammatory properties of the recommended dietary pattern, which may reduce the risk of depression 55,56 . Depression is often accompanied by elevated levels of CRP, 57,58 and inflammation has been linked to depression through mechanisms such as insulin resistance and interactions with monoamine metabolism 59–61 . Higher scores on the AHEI‐2010 are associated with a lower risk of CRP 62 and insulin resistance 63 due, in part, to a reduced risk of obesity 64 .…”

Adherence to the 2018 AHA cholesterol management guideline in hyperlipidemia treatment among adults in an outpatient setting

“…Recent clinical studies have uncovered intriguing findings about the effectiveness of statin therapy for patients at risk of CVD. Statins have been shown to significantly reduce LDL-C levels, thereby improving the lipid profile and offering better protection against cardiovascular events for high-risk patients when compared to conventional lipid-lowering treatments ( 9 , 10 ). Considering statin's properties and the existing clinical evidence, this class of anti-atherosclerosis drugs is the preferred therapeutic approach for both primary and secondary prevention of CVDs ( 11 ).…”